Merit Medical Systems

Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merit Medical Systems reports robust Q4 performance and eyes growth

Merit Medical Systems delivered a strong Q4 performance with revenue growth, increased gross profit, and exceeding net income expectations.
While facing challenges in certain segments and regulatory compliance, the company remains optimistic about growth opportunities and operational improvements.
Strategic pricing initiatives and a focus on achieving financial targets position Merit Medical for continued success and potential expansion through M&A activities.
The company's commitment to discipline, prioritization, and operational excellence underscores its resilience and potential for sustained growth in the future.

Merit Medical Systems posts strong Q1 results, eyes debt reduction

Merit Medical Systems delivered robust financial results in Q1 2023, showcasing growth in revenue, operating income, and net income. The company maintains its financial guidance for 2023, emphasizing a commitment to debt reduction and free cash flow targets. Analyst inquiries highlighted areas for improvement and strategic focus moving forward.

Merit Medical Systems reports robust Q2 earnings amidst strategic acquisitions

Merit Medical Systems delivered strong financial performance in Q2 2023, marked by revenue growth, improved profitability, and strategic acquisitions. While facing challenges in the Endoscopy segment and uncertainties in international markets, the company remains focused on leveraging opportunities in catch-up procedures and strategic M&A for sustainable growth.

Merit Medical Systems excels in Q3, eyes growth opportunities

Merit Medical Systems delivered a strong Q3 performance with notable revenue growth, profit increases, and enhanced net income and EPS.
While facing challenges like margin pressure and regional headwinds, the company remains focused on long-term growth strategies and operational efficiency.
With opportunities for revenue expansion, product advancements, and margin improvements on the horizon, Merit Medical Systems is poised for continued success and shareholder value creation.

Merit Medical Systems excels in Q4 2023, eyes strategic growth

Merit Medical Systems delivered strong financial results in Q4 2023, driven by revenue growth and margin expansion.
The company's strategic initiatives and focus on operational efficiency position it well for future growth and profitability.
Challenges such as SKU rationalization and China revenue decline require careful management and strategic planning.
Opportunities in M&A, pricing power initiatives, R&D investments, and gross margin expansion strategies offer avenues for continued success.

Merit Medical Systems excels in Q1, eyes growth opportunities

Merit Medical Systems delivered strong Q1 results with revenue growth and profitability improvements, driven by operational progress and strategic focus on innovation.
While facing challenges such as pricing pressures in China and debt reduction strategies, the company remains poised for growth through new opportunities and market strategies.
With a solid performance in Q1 and positive Q2 guidance, Merit Medical Systems demonstrates resilience and a strategic approach to navigating industry challenges.
The company's commitment to financial stability, innovation, and shareholder value sets a strong foundation for future growth and market competitiveness.

Merit Medical Systems reports robust Q3 results amidst supply challenges

Merit Medical Systems delivered strong financial results in Q3, driven by revenue growth and margin improvement.
The company's strategic acquisition and focus on innovation position it well for future growth despite supply chain disruptions.
Challenges in supply chain management and analyst inquiries highlight areas for ongoing attention and improvement.
Overall, Merit Medical Systems maintains a positive outlook on its performance and growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

After launching three new products and posting a second quarter of rising EPS growth, medical devices leader Merit Medical Systems is probing a new buy point. The post Medical Devices Stock Pumps Up Buy Point With New Innovations appeared first on Investor's Business Daily.

Medical Devices Stock Pumps Up Buy Point With New Innovations

CONMED

MMSI vs. CNMD: Which Stock Is the Better Value Option?

MMSI vs. CNMD: Which Stock Should Value Investors Buy Now?

SALT LAKE CITY, Nov. 02, 2022 (GLOBE NEWSWIRE) -- TO: ALL OWNERS OF MERIT MEDICAL SYSTEMS, INC. (“MERIT” OR THE “COMPANY”) COMMON STOCK AS OF AUGUST 17, 2022 (“CURRENT MERIT STOCKHOLDERS”)

Summary Notice to Current Merit Medical Systems, Inc. Stockholders of Derivative Action and Settlement Hearing

Merit's long-time executive, Joe Wright, has been appointed to the new role of Chief Commercial Officer and will be responsible for leading all commercial activities for the global organization. Merit's long-time executive, Joe Wright, has been appointed to the new role of Chief Commercial Officer and will be responsible for leading all commercial activities for the global organization.

Merit Medical Announces the Appointment of Joe Wright to Chief Commercial Officer

Merit Medical (MMSI), in the third quarter, benefits from revenue growth in both its segments and the majority of product categories within its Cardiovascular unit.

Merit Medical (MMSI) Q3 Earnings Beat, FY22 View Revised

Merit Medical Systems, Inc. (NASDAQ:MMSI ) Q3 2022 Earnings Conference Call October 26, 2022 5:00 PM ET Company Participants Fred Lampropoulos - President & CEO Brian Lloyd - Chief Legal Officer & Corporate Secretary Raul Parra - CFO Conference Call Participants Jayson Bedford - Raymond James Larry Biegelsen - Wells Fargo Mike Matson - Needham & Company William Plovanic - Canaccord Genuity Jason Bednar - Piper Sandler Jim Sidoti - Sidoti & Company Michael Petuski - Barrington Research Operator Good day and thank you for standing by. Welcome to the Merit Medical Systems Third Quarter 2022 Earnings Conference Call.

Merit Medical Systems, Inc. (MMSI) Fred Lampropoulos on Q3 2022 Results - Earnings Call Transcript

Merit Medical (MMSI) delivered earnings and revenue surprises of 20.75% and 5.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Merit Medical (MMSI) Q3 Earnings and Revenues Top Estimates

* Constant currency revenue; constant currency revenue, organic; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross profit and margin; and free cash flow are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

Merit Medical Reports Results for Quarter Ended September 30, 2022

SOUTH JORDAN, Utah, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2022, after the close of the stock market on Wednesday, October 26, 2022.

Merit Medical Systems to Announce Third Quarter Results on October 26, 2022

Merit Medical's (MMSI) launch of the TEMNO Elite Soft Tissue Biopsy System will boost its portfolio of biopsy devices.

Merit Medical (MMSI) Launches New Soft Tissue Biopsy System

Advanced device offers 72% larger samples, simplifies tissue retrieval, and enhances patient safety Advanced device offers 72% larger samples, simplifies tissue retrieval, and enhances patient safety

Merit Medical Launches the TEMNO Elite™ Soft Tissue Biopsy System

New long guide sheath accesses difficult anatomy in the peripheral vasculature, expanding treatment to more patients

Merit Medical Launches the Prelude Roadster™ Guide Sheath

Wilmington, Delaware--(Newsfile Corp. - September 6, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Merit Medical Systems, Inc. (NASDAQ: MMSI) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-merit-medical-systems.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Merit Medical Systems, Inc.

Modern design advances patient care by combining hemostasis with innovative cooling capability Modern design advances patient care by combining hemostasis with innovative cooling capability

Merit Medical Launches SafeGuard Focus Cool™ Compression Device

Merit Medical (MMSI), in the second quarter, benefits from revenue growth in both its segments and from all product categories within its Cardiovascular unit.

Merit Medical (MMSI) Q2 Earnings Beat, FY22 View Revised

Merit Medical Systems, Inc. (NASDAQ:MMSI ) Q2 2022 Earnings Conference Call July 27, 2022 5:00 PM ET Company Participants Fred Lampropoulos - Founder, Chairman & Chief Executive Officer Brian Lloyd - Chief Legal Officer & Corporate Secretary Raul Parra - Chief Financial Officer & Treasurer Conference Call Participants Operator Welcome to the Second Quarter of Fiscal Year 2022 Earnings Conference Call for Merit Medical Systems, Inc. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.

Merit Medical Systems, Inc. (MMSI) CEO Fred Lampropoulos on Q2 2022 Results - Earnings Call Transcript

Merit Medical (MMSI) delivered earnings and revenue surprises of 25.86% and 4.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Merit Medical (MMSI) Q2 Earnings and Revenues Surpass Estimates

*  Constant currency revenue; constant currency revenue, organic; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross margin; and free cash flow are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

Merit Medical Reports Results for Quarter Ended June 30, 2022

Only balloon configuration specifically designed to dilate small airways, providing minimally invasive treatment to patients with lung obstructions Only balloon configuration specifically designed to dilate small airways, providing minimally invasive treatment to patients with lung obstructions

Merit Medical Launches Smallest and Shortest Configuration of Elation® Pulmonary Balloon Dilator to Help Meet Critical Patient Need

SOUTH JORDAN, Utah, July 14, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2022, after the close of the stock market on Wednesday, July 27, 2022.

Merit Medical Systems to Announce Second Quarter Results on July 27, 2022

Prospective, observational study to assess the clinical utility of the SCOUT® Radar Localization System (SCOUT) in real-world practice Prospective, observational study to assess the clinical utility of the SCOUT® Radar Localization System (SCOUT) in real-world practice

First Patient Enrolled in the Streamlined Localization (STREAMLoc) Registry Study Using SCOUT® at Biopsy in Canada

Merit Medical's (MMSI) latest launch will likely aid in precisely targeting affected tissues, thereby resulting in more successful surgeries and improved patient outcomes.

Merit Medical's (MMSI) New Launch to Improve Patient Outcome

Reduced profile designed to optimize use in lymph nodes and other difficult-to-localize areas and enable placement at time of biopsy or pre-neoadjuvant chemotherapy. Reduced profile designed to optimize use in lymph nodes and other difficult-to-localize areas and enable placement at time of biopsy or pre-neoadjuvant chemotherapy.

New SCOUT® Mini Reflector Provides Physicians with a Compact Design for Greater Utility

Prospective, international, multicenter, observational study to assess the real-world safety and efficacy of the WRAPSODY Cell-Impermeable Endoprosthesis Prospective, international, multicenter, observational study to assess the real-world safety and efficacy of the WRAPSODY Cell-Impermeable Endoprosthesis

First Patient Enrolled in Merit Medical's WRAPSODY™ Registry (WRAP) Study

Utah Governor and local officials joined Merit in recognizing green initiative to save 4 million gallons of water each year Utah Governor and local officials joined Merit in recognizing green initiative to save 4 million gallons of water each year

News for Merit Medical Systems Stock (MMSI)